"A study in mice reveals an elegant circuit within the developing visual system that helps dictate how the eyes connect to the brain. The research, funded by the National Institutes of Health, has implications for treating amblyopia, a vision diso"...
No information is available on overdosage of OptiPranolol (metipranolol ophthalmic solution) Ophthalmic Solution in humans. The symptoms which might be expected with an overdose of a systemically administered beta-adrenergic receptor blocking agent are bradycardia, hypotension and acute cardiac failure.
Hypersensitivity to any component of this product.
OptiPranolol (metipranolol ophthalmic solution) Ophthalmic Solution is contraindicated in patients with bronchial asthma or a history of bronchial asthma, or severe chronic obstructive pulmonary disease; symptomatic sinus bradycardia; greater than a first degree atrioventricular block; cardiogenic shock; or overt cardiac failure.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 11/13/2008
Additional Optipranolol Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get breaking medical news.